capsule
Sponsors
Nanfang Hospital, Southern Medical University, Morphic Therapeutic Inc., Kartos Therapeutics Inc., Mirum Pharmaceuticals Inc., Acerta Pharma B.V.
Conditions
Advanced or Recurrent Endometrial CancerFungal infectionGastric diseasesMantle Cell LymphomaMetastatic Castration-Resistant Prostate CancerMetastatic Medullary Thyroid CancerModerately to Severely Active Crohn’s DiseaseModerately to severely active ulcerative colitis
Phase 1
Phase 2
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
Active, not recruitingCTIS2022-500953-17-00
Start: 2023-03-23Target: 172Updated: 2025-12-11
A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Active, not recruitingCTIS2023-505764-11-00
Start: 2022-06-10Target: 105Updated: 2025-11-24
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
CompletedCTIS2022-502196-31-00
Start: 2023-08-21End: 2024-07-26Target: 140Updated: 2024-05-15
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 2 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET)
RecruitingCTIS2023-508158-24-00
Start: 2024-06-25Target: 150Updated: 2025-12-02
TSPO ligands in the treatment of depression: proof-of-concept of efficacy and underlying mechanisms of action
CompletedCTIS2024-512698-29-00
Start: 2024-07-25End: 2025-11-21Target: 50Updated: 2025-06-26
The effect of amantadine as add-on therapy for motor fluctuations in advanced Parkinson’s disease: a randomized double-blinded placebo-controlled trial
RecruitingCTIS2023-509728-16-00
Start: 2025-10-10Target: 132Updated: 2026-01-23
A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR)
CompletedCTIS2024-517406-29-00
Start: 2022-07-26End: 2025-04-25Target: 72Updated: 2025-02-14
Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
Active, not recruitingCTIS2023-509396-16-00
Start: 2021-11-08Target: 136Updated: 2025-12-05
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Active, not recruitingCTIS2023-509354-58-00
Start: 2017-07-14Target: 198Updated: 2025-07-29
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingCTIS2023-504724-25-00
Start: 2024-10-16Target: 126Updated: 2025-10-06
Phase 4
Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections (FOCUS)
Not yet recruitingCTIS2024-518305-17-01
Target: 30Updated: 2024-12-02
A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Active, not recruitingCTIS2024-516480-90-00
Start: 2015-11-23Target: 10Updated: 2025-12-17
Unknown Phase
Standing type magnetically guided capsule versus gastroscopy for gastric examination
Active, not recruitingChiCTR1800018346
Start: 2018-04-17Updated: 2018-09-17
A Prospective, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy of Bacillus Coagulans Unique IS2 on Improving Bowel Movement Characteristics, Gastrointestinal-related Symptoms and Quality of Life in Healthy Adult Participants
CompletedNCT05123664
Start: 2022-04-11End: 2023-12-20Updated: 2024-03-06